You are here

VaxNewMO

Company Information
Address
4447 McPherson Ave
Saint Louis, MO 63108
United States



Information

DUNS: 080343938

# of Employees: 1


Ownership Information

HUBZone Owned: No

Socially and Economically Disadvantaged: No

Woman Owned: No



Award Charts




Award Listing

  1. Towards a New Generation of Glycoengineered Pneumococcal Bioconjugate Vaccines

    Amount: $931,060.00

    PROJECT SUMMARY Pneumococcal conjugate vaccines (PCVs), composed of a pneumococcal polysaccharide covalently linked to a carrier protein, are life-saving prophylactics used to prevent pneumococcal dis ...

    SBIRPhase II2020Department of Health and Human Services National Institutes of Health
  2. Development of a bioconjugate vaccine against Group B Streptococcus

    Amount: $580,104.00

    PROJECT SUMMARY Streptococcus agalactiae, commonly referred to as Group B Streptococcus (GBS), is a leading cause of neonatal meningitis and sepsis worldwide as well as an agent of invasive disease in ...

    STTRPhase I2019Department of Health and Human Services National Institutes of Health
  3. Glycoengineering a bioconjugate vaccine against Klebsiella pneumoniae

    Amount: $299,999.00

    PROJECT SUMMARY Klebsiella pneumoniae is an increasingly prevalent drug resistant nosocomial pathogenCommonlyKpneumoniae isolates are carbapenem resistantwhich are referred to as carbapenem resistant ...

    STTRPhase I2018Department of Health and Human Services National Institutes of Health
  4. Towards a New Generation of Glycoengineered Pneumococcal Bioconjugate Vaccines

    Amount: $210,129.00

    PROJECT SUMMARY Pneumococcal pneumonia remains the leading cause of bacterial pneumonia in both children under years of age and adults over years of age The standard preventative therapy is the ...

    STTRPhase I2017Department of Health and Human Services National Institutes of Health
US Flag An Official Website of the United States Government